Every Form 4 that Neuronetics, Inc. (STIM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow STIM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STIM filings page.
Neuronetics, Inc. insider Jorey Chernett, a ten percent owner, reported mixed transactions. On 2026-08-14 he purchased 14,000 shares of common stock at a weighted average price of $3.16 per share, in multiple trades between $3.13 and $3.17, bringing his direct holdings to 10,602,988 shares. On 2026-08-13 he sold 100 call option contracts on Neuronetics common stock (underlying 10,000 shares) at $3.21 per option-share with a $5.00 strike price expiring on 2027-02-19, leaving no remaining position in these options. The option sale is described as a matchable transaction under Section 16(b), and Chernett states he intends to disgorge the calculated short-swing profit to Neuronetics. The transactions were not reported as made under a Rule 10b5-1 trading plan.
Naor Nir reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. granted its EVP, CFO & Treasurer, Naor Nir, a 500,000-share restricted stock unit (RSU) award of common stock on July 23, 2026. The RSUs vest in four equal installments beginning on July 23, 2027, subject to his continuous employment. Each RSU represents a contingent right to receive one share of Neuronetics common stock, resulting in 500,000 shares reported as directly held after the award.
Neuronetics, Inc. disclosed that large shareholder Jorey Chernett, a more than ten percent owner, made an open-market purchase of 35,000 shares of Common Stock on 2026-07-14 at a weighted average price of $1.78 per share, increasing his direct holdings to 10,588,988 shares. The shares were bought in multiple trades between $1.77 and $1.79.
Neuronetics, Inc. director Avinash Amin reported internal share transfers among affiliated investment funds, with no open‑market buying or selling. On 2026-06-15, Amin transferred 4,634 shares of common stock to Madryn Health Partners II, LP, 34,932 shares to Madryn Health Partners II (Cayman Master), LP, and 2,934 shares to Madryn Select Opportunities, LP.
The footnotes state these transfers involved shares received as director compensation and were made for no consideration, as provided in each fund’s partnership agreement. After these J-code restructuring transactions, Amin directly holds 30,000 shares of Neuronetics common stock.
Neuronetics, Inc. insider filing reports internal share transfers among investment funds advised by Madryn Asset Management related to director compensation. On May 28 and June 15, entities associated with Madryn reallocated a total of 72,500 shares of common stock, all coded as other acquisitions or dispositions.
The shares originated from restricted stock units awarded to director Avinash Amin, which are held for the benefit of Madryn Health Partners II, Madryn Health Partners II (Cayman Master), and Madryn Select Opportunities under their partnership agreements. Each transfer was made for no consideration and reflects reallocations among these funds rather than open‑market trades.
After these transactions, indirect holdings reported include 2,269,073 shares for one Madryn fund, 17,104,530 shares for another, and 1,435,958 shares for a third. The reporting persons state that they may be deemed to beneficially own these shares through advisory and general partner roles, but each disclaims beneficial ownership except to the extent of any pecuniary interest.
Neuronetics, Inc. director Megan Rosengarten reported receiving an award of 30,000 restricted stock units of common stock. The RSU grant is a form of equity compensation and carries no cash exercise price.
The award vests on the earlier of May 28, 2027, or her Board-approved separation of service or a change in control of Neuronetics, in each case requiring her continuous service through that date. After this grant, she holds 170,890 shares and RSUs of Neuronetics common stock directly.
Neuronetics, Inc. director Glenn P. Muir received a grant of 30,000 restricted stock units (RSUs) of common stock at no cost. The RSU award vests on the earlier of May 28, 2027, or a Board-approved separation of service or change in control, subject to his continuous service.
Each RSU converts into one share of Neuronetics common stock when it vests. Following this equity award, Muir’s reported direct holdings increased to 401,816 shares of common stock.
Cucuz Sasha reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. director Sasha Cucuz received an award of 30,000 restricted stock units (RSUs) of common stock. The RSUs vest on the earlier of May 28, 2027 or a Board-approved separation of service or change in control, in each case requiring continuous service until that date.
Each RSU represents a contingent right to receive one share of Neuronetics common stock. Following this grant, Cucuz directly holds 1,542,798 shares. Separate indirectly held shares are reported as held by Greybrook Health Inc. (516,084 shares) and Greybrook Realty Partners Inc. (2,042 shares), with beneficial ownership of these indirect holdings disclaimed except to the extent of his pecuniary interest.
CONLEY SHERYL L reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. director Sheryl L. Conley reported receiving an equity award in the form of restricted stock units. The award covers 30,000 RSUs, with no cash purchase price. Each RSU represents the right to receive one share of Neuronetics common stock.
The RSUs vest on the earlier of May 28, 2027, or her Board-approved separation from service or a change in control of Neuronetics, in each case conditioned on her continuous service through that date. After this grant, Conley holds 251,716 shares of common stock directly.
Neuronetics, Inc. director Robert Cascella received a grant of 36,250 restricted stock units of common stock as equity compensation. The award has no cash exercise price and will vest on the earlier of May 28, 2027, or a Board-approved separation or change in control, subject to his continuous service. After this grant, Cascella holds 625,017 shares of Neuronetics common stock directly.
Neuronetics, Inc. director Avinash Amin reported an equity compensation grant in the form of 30,000 restricted stock units of common stock. The award vests on the earlier of May 28, 2027, a Board-approved separation of service, or a change in control, in each case subject to his continuous service. Each RSU converts into one share of common stock upon vesting. Following this grant, he holds 72,500 shares directly.
Neuronetics, Inc. former EVP, CFO and Treasurer Steven Pfanstiel corrected a prior insider report and now shows an open‑market sale of 8,569 shares of common stock on March 19, 2026 at a weighted average price of $1.34 per share.
The footnotes explain these were non‑discretionary sales made to satisfy his tax withholding obligation upon vesting of a performance restricted stock unit award. After this transaction, he directly holds 836,643 shares of Neuronetics common stock.
Neuronetics, Inc. large shareholder Jorey Chernett bought 100,000 shares of common stock in an open-market transaction. The shares were purchased at an average price of $1.17 per share. Following this buy, Chernett directly holds 10,553,988 Neuronetics shares.
Neuronetics, Inc. large shareholder Jorey Chernett reported an open-market purchase of 475,000 shares of Common Stock. The shares were bought at a weighted average price of $1.34 per share in multiple trades. After this transaction, Chernett directly holds 10,453,988 shares of Neuronetics common stock.
The filing notes that individual trade prices on the transaction date ranged from $1.27 to $1.36 per share, and Chernett has agreed to provide full trade-level detail upon request.
Neuronetics, Inc. insider Jorey Chernett purchased 200,000 shares of Common Stock in open-market transactions. He bought 100,000 shares on April 20 and another 100,000 shares on April 21 at weighted average prices around $1.51–$1.58 per share, executed in multiple trades within stated price ranges. After these purchases, he directly holds 9,978,988 shares of Neuronetics common stock.
Madryn-affiliated funds reallocated Neuronetics, Inc. common stock between related vehicles. Two bona fide gift transfers on July 10, 2025 moved a total of 674,624 shares of common stock for no consideration between Madryn Health Partners II, LP and Madryn Health Partners II (Cayman Master), LP for fund administration purposes.
Following the transfers, one fund held 1,430,953 shares of Neuronetics common stock and the other held 17,044,940 shares. Madryn Asset Management, LP serves as investment advisor to both funds, and related Madryn entities may be deemed beneficial owners, while each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Neuronetics, Inc. ten percent owner Jorey Chernett reported an open-market purchase of 385,442 shares of common stock at a weighted average price of $1.25 per share. After this transaction, Chernett directly beneficially owned 9,778,988 shares of Neuronetics common stock.
The shares were acquired in multiple trades at prices ranging from $1.23 to $1.26 per share, calculated on a weighted average basis. The filing also corrects a prior clerical error, noting that the previously reported beneficial ownership had been understated by 270 shares.
Neuronetics, Inc. major shareholder Jorey Chernett reported an open-market purchase of 500,000 shares of Common Stock at a weighted average price of $1.35 per share. The shares were bought in multiple trades between $1.28 and $1.41. Following this transaction, Chernett directly holds 9,393,276 shares.
Neuronetics, Inc. 10% owner Jorey Chernett reported open-market purchases of a total of 150,000 shares of common stock. The buys occurred on March 25 and March 26 at reported prices of $1.40 and $1.44 per share, respectively. After these transactions, Chernett directly owns 8,893,276 Neuronetics shares. A footnote explains that one purchase reflects a weighted-average price for multiple trades executed between $1.38 and $1.42 per share.
Neuronetics EVP, CFO and Treasurer Steven Pfanstiel reported an open-market sale of 16,431 shares of common stock at a weighted average price of $1.34 per share. According to the footnotes, these were non-discretionary sales made solely to satisfy tax withholding obligations upon vesting of a performance restricted stock unit award. After the transaction, Pfanstiel directly holds 828,781 shares of Neuronetics common stock, indicating this was a relatively small, tax-driven adjustment to his overall position rather than a discretionary portfolio move.
Former officer and director Keith J. Sullivan of Neuronetics, Inc. reported an open-market coded sale of 46,289 shares of common stock at a weighted average price of $1.34 per share. According to the footnotes, these were non-discretionary sales made solely to satisfy his tax withholding obligation upon vesting of a performance restricted stock unit award.
The shares were sold in multiple trades at prices ranging from $1.48 to $1.20 per share. After these transactions, Sullivan directly holds 1,590,924 shares of Neuronetics common stock, indicating he retained a substantial equity position following the tax-related disposition.
Neuronetics, Inc. executive William Andrew Macan reported an open-market sale of 16,005 shares of common stock at a weighted average price of $1.34 per share. According to the disclosure, these were non-discretionary sales made solely to cover tax withholding upon vesting of a performance restricted stock unit award, and he continues to hold 897,270 shares directly.
REUVERS DANIEL L. reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. President and CEO Daniel L. Reuvers reported an equity compensation award of 1,500,000 shares of common stock on March 23, 2026, coded as a grant. The award is structured as restricted stock units that vest in three equal annual installments beginning on March 23, 2027, subject to his continuous service. Each RSU gives a contingent right to receive one share of common stock, and following this award he reports 1,500,000 shares/units held directly.
Neuronetics, Inc. insider activity: 10% owner Jorey Chernett purchased 169,472 shares of Neuronetics common stock in an open-market transaction at a weighted average price of $1.41 per share. The footnote states the trades occurred in multiple transactions between $1.36 and $1.44 per share, rounded to the nearest cent.
Following this purchase, Chernett directly holds 8,743,276 Neuronetics shares. The filing notes he can provide detailed breakdowns of the number of shares bought at each specific price upon request by the company, its security holders, or the SEC staff.
Neuronetics, Inc. 10% owner Jorey Chernett reported significant open-market buying of the company’s common stock. On March 18, 2026, he purchased 607,400 shares at a weighted average price of $1.35 per share in multiple trades. On March 19, 2026, he bought an additional 450,000 shares at a weighted average price of $1.33 per share, also across multiple transactions. Following these purchases, Chernett directly owns 8,573,804 shares of Neuronetics common stock.
Sullivan Keith J reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. reported that President and CEO Keith J. Sullivan received a grant of 112,500 shares of common stock. The shares were issued for no cash consideration upon satisfaction of performance criteria tied to performance-based restricted stock units. Following this award, Sullivan directly holds 1,637,213 shares of Neuronetics common stock. This is a compensation-related equity award rather than an open-market purchase.
Neuronetics, Inc. reported that its EVP, CLO and CS, William Andrew Macan, received an award of 33,750 shares of common stock. These shares were granted for no cash consideration after performance criteria tied to performance-based restricted stock units were satisfied. Following this equity award, his directly held common stock position increased to 913,275 shares, highlighting a compensation-related, non-market acquisition rather than an open-market purchase.
Pfanstiel Steven reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. reported that EVP, CFO and Treasurer Steven Pfanstiel received an equity grant of 25,000 restricted stock units (RSUs). Each RSU represents a right to receive one share of common stock, vesting in three equal annual installments beginning on March 17, 2027, subject to his continuous service. Following this award, Pfanstiel is shown as holding 845,212 shares of common stock directly.
Neuronetics, Inc. major shareholder Jorey Chernett reported an open-market purchase of 531,000 shares of common stock at a weighted average price of $1.16 per share. The filing notes the shares were bought in multiple trades between $0.91 and $1.31 per share. Following this transaction, Chernett directly owns 7,516,404 shares of Neuronetics common stock.
Neuronetics, Inc. executive William Andrew Macan, EVP, CLO and CS, reported a small automatic share sale tied to equity compensation. On March 4, 2026, he disposed of 609 shares of common stock in open-market transactions at a weighted average price of $1.34 per share, with individual prices ranging from $1.28 to $1.39. The footnotes state these were non-discretionary sales made solely to satisfy his tax withholding obligation upon the vesting of a restricted stock unit award. After this tax-related sale, he continued to own 879,525 common shares directly.
Neuronetics, Inc. executive William Andrew Macan, EVP, CLO and CS, reported an open-market sale of 3,427 shares of common stock at a weighted average price of $1.35 per share. The sale was a non-discretionary transaction to cover tax withholding upon vesting of a restricted stock unit award, and he now holds 880,134 shares directly.
Neuronetics, Inc. President and CEO Keith J. Sullivan reported an open-market sale of 8,452 shares of common stock at a reported weighted average price of $1.35 per share. According to the filing, these were non-discretionary sales to satisfy tax withholding obligations upon vesting of a restricted stock unit award. After the transaction, Sullivan directly owned 1,524,713 shares of Neuronetics common stock.
Neuronetics, Inc. reported that EVP, CFO and Treasurer Steven Pfanstiel acquired an award of 250,000 shares of common stock in the form of restricted stock units. The award was granted at no purchase price.
The RSUs vest in three equal annual installments beginning on February 23, 2027, as long as he remains in continuous service through each vesting date. After this grant, his directly held common stock position reported in the filing totals 820,212 shares.
Neuronetics, Inc. reported that executive vice president, chief legal officer and corporate secretary William Andrew Macan acquired 210,000 restricted stock units (RSUs) of common stock as an equity award. Each RSU represents the right to receive one Neuronetics common share.
The RSU award vests in three equal annual installments beginning on February 23, 2027, subject to Mr. Macan’s continuous service through each vesting date. Following this grant, he directly holds 883,561 shares of Neuronetics common stock. This is a non-cash, stock-based compensation grant rather than an open‑market purchase.
Neuronetics, Inc. director and CEO Keith J. Sullivan reported an open-market sale of 33,847 shares of common stock at a weighted average price of $1.65 per share. After this transaction, he directly holds 1,533,165 shares of Neuronetics common stock.
According to the footnotes, these were non-discretionary sales made solely to satisfy the reporting person's tax withholding obligation upon vesting of a restricted stock unit award. The shares were sold in multiple trades at prices ranging from $1.56 to $1.72 per share.
Neuronetics, Inc. executive William Andrew Macan reported an open-market sale of 14,120 shares of common stock at a weighted average price of $1.65 per share on February 12, 2026. According to the disclosure, these were non-discretionary sales made solely to cover tax withholding obligations triggered by the vesting of a restricted stock unit award.
After this transaction, Macan beneficially owned 673,561 shares of Neuronetics common stock directly. The price range for the individual trades was between $1.56 and $1.72 per share, with the insider indicating that detailed trade breakdowns are available upon request.
Neuronetics, Inc. executive William Andrew Macan, EVP, CLO and CS, reported selling 3,485 shares of common stock on February 10, 2026. The Form 4 notes these were non-discretionary sales made solely to satisfy tax withholding on the vesting of a restricted stock unit award, at a weighted average price of $1.55 per share. After this transaction, Macan directly beneficially owned 687,681 shares of Neuronetics common stock.
Neuronetics, Inc. President and CEO Keith J. Sullivan reported an open-market sale of 40,976 shares of common stock on February 10, 2026 at a weighted average price of $1.55 per share. According to the disclosure, these were non-discretionary sales made solely to satisfy his tax withholding obligation upon the vesting of a portion of a restricted stock unit award.
After this transaction, Sullivan directly beneficially owned 1,567,012 shares of Neuronetics common stock.
Neuronetics (STIM) reported an insider equity award on Form 4. A director acquired 10,531 shares of common stock on 10/20/2025 through a restricted stock unit award that vested immediately, elected in lieu of a cash retainer. The transaction was recorded at $0 per unit, consistent with RSU grants.
Following this transaction, the director’s beneficial ownership stands at 588,767 shares, held directly.
Neuronetics, Inc. (STIM) reported an insider equity award. On 10/20/2025, a director acquired 7,326 shares of common stock at $0, coded “A,” under the company’s non-employee director compensation plan. The award reflects an election to receive stock in lieu of a cash retainer, delivered as restricted stock units that vested immediately upon grant, with each RSU equal to one share.
Following the transaction, the director beneficially owned 221,716 shares, held directly.
Neuronetics, Inc. (STIM) reported an insider equity award by a director. On 10/20/2025, the director acquired 7,554 shares of common stock via a restricted stock unit (RSU) grant at $0 under the non-employee directors compensation plan, electing stock in lieu of a cash retainer.
The RSU award vested immediately upon grant, with each RSU representing one share. Following the transaction, the director’s beneficial ownership stands at 371,816 shares, held directly.
Neuronetics, Inc. (STIM) reported an insider transaction by a director. On 10/20/2025, the director acquired 6,410 shares of common stock via a restricted stock unit (RSU) grant that vested immediately and was elected in lieu of a cash retainer under the non-employee directors compensation plan. The RSU acquisition price was $0, with each RSU representing one share.
Following the transaction, the director beneficially owned 1,512,798 shares directly. The filing also lists indirect beneficial ownership of 516,084 shares through Greybrook Health Inc. and 2,042 shares through Greybrook Realty Partners Inc.